查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2154572

RNA修飾的假尿苷市場：全球市場預測，2026-2032年

RNA Modified Pseudouridine Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，RNA 修飾的假尿苷市場將成長至 2.3548 億美元，複合年成長率為 12.05%。

主要市場統計數據
基準年 2025 1.0615億美元
預計年份：2026年 1.2415億美元
預測年份 2032 2.3548億美元
複合年成長率 (%) 12.05%

RNA修飾的假尿苷：概述

RNA修飾的假尿苷是化學修飾的核苷，用於改變RNA的穩定性、翻譯、固有免疫識別和藥物性能。其應用範圍涵蓋傳訊RNA療法、疫苗、基因編輯系統和研究試劑。研發重點在於可重複的合成、高純度的分析控制、可擴展的生產，以及建立證據證明特定修飾譜與臨床和功能結果之間的相關性。

平台整合正在改變RNA開發的方式。

目前，RNA設計的研究格局正從概念驗證（PoC）轉向整合序列設計、核苷化學、遞送系統、製程開發和品管的一體化開發平台。人們越來越關注雜質譜、免疫活化、儲存穩定性以及批間一致性。加之監管要求，研發人員被促使在藥物發現、臨床開發和生產的各個階段對修飾RNA材料進行更全面的表徵。

人工智慧可以加快設計和品管工作流程。

人工智慧可以透過序列優先排序、結構和翻譯行為建模、潛在免疫抗原性識別以及分析流程最佳化等方式輔助研究修飾RNA。機器學習工具還可以幫助揭示合成條件與雜質模式或產品性能之間的關聯。其價值取決於正確註釋的實驗數據、透明的檢驗、人工審核以及控制措施，以確保模型輸出不會取代實驗室數據、毒理學數據或監管證據。

區域洞察：RNA生態系統的各個面向都在不斷擴展。

北美擁有先進的生物技術基礎設施、轉化研究能力和成熟的監管合規經驗。歐洲受惠於強大的學術網路、製藥生產專長和協調一致的科學研究計畫。同時，亞太地區在核酸研究、製程開發和生物製造方面的能力正在不斷提升。在拉丁美洲，隨著公共衛生優先事項和技術取得的推動，研發與生產合作日益加強。中東強調創新生態系統和專業醫療保健投資，而非洲的機會則與技術轉移、本地分析能力和區域製造業韌性密切相關。

集團洞察：政策協調和供應鏈韌性至關重要。

東南亞國協能夠從協調的製造、研究合作和區域供應鏈發展中獲益。金磚國家在科學、工業和公共衛生領域擁有相當的實力，但需要加強監管和品管系統之間的互通性。歐盟重視統一標準和先進的生命科學研究，而七國集團則擁有豐富的財政、研究和監管資源。海灣合作理事會成員國優先發展生物技術多元化和基礎設施建設，而北約成員國則可以利用其廣泛的科學網路和與關鍵生物供應鏈相關的韌性計劃。

國家概況：多元優勢塑造採納路徑

美國和加拿大擁有強大的轉化研究、監管和生產能力。德國、法國、義大利、西班牙和英國貢獻了成熟的生物醫學研究、臨床基礎設施和先進的藥品品質系統。中國、日本、韓國、印度和澳洲將不斷發展的RNA研究與其在生產、學術和醫療保健方面的獨特優勢相結合。巴西和墨西哥是拉丁美洲重要的研究、公共衛生計畫和區域生產中心。俄羅斯保持其科學和工業實力，但合作條件和獲取國際資源的途徑可能會影響其發展方向。

行業領導者的優先事項

產業領導者應建立對修飾核苷品質的端對端控制，包括檢驗其身分、純度、殘留雜質和功能性檢測。化學設計應與遞送、轉化、免疫抗原性和穩定性數據相結合，而不是單獨最佳化每個組件。多元化合格供應商、投資區域分析和生產能力以及儘早與監管機構溝通可以降低實施風險。人工智慧計畫應專注於可審計的應用案例，並以健全的數據管治為基礎，與學術界、臨床機構和生產機構夥伴關係可以加速證據的產生。

調查方法：基於實證的市場狀況綜合分析

本執行摘要根據特定RNA修飾假尿苷的範圍，按技術、應用、地區、相關人員群體和國家對研究結果進行分類。這些見解是基於修飾RNA開發、生物製造、監管、供應鏈管理和人工智慧應用等方面的既定特徵。本分析有意排除市場估算和預測、市場佔有率、預測以及公司特定聲明。關於地區和群體的觀察是對機構能力和發展狀況的比較性解讀，而非量化排名。

結論：建設時應注重性能、品質和韌性。

RNA修飾的假尿苷正從單純的化學元素演變為支撐更廣泛的RNA技術平台的基礎模組。永續發展取決於修飾選擇與生物性能、遞送、可生產性和監管證據的一致性。那些能夠將嚴謹的分析、可擴展的生產、負責任的人工智慧和具有地域適應性的夥伴關係關係相結合的機構，將更有能力將實驗室的進展轉化為可靠的治療藥物、疫苗和研究應用。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 RNA修飾的假尿苷市場：依類型

  • 1-甲基吡咯尿苷
  • 假尿苷

第8章 RNA修飾的假尿苷市場：依形式

  • 液體
  • 粉末

第9章 RNA修飾的假尿苷市場：依純度等級分類

  • 分析級
  • 高效液相層析級

第10章：RNA修飾的假尿苷市場：依應用領域分類

  • 學術研究
  • 診斷調查
  • mRNA治療藥物
  • 藥效疫苗

第11章 RNA修飾的假尿苷市場：依最終用戶分類

  • 學術研究機構
  • 受託研究機構
  • 製藥和生物技術公司

第12章 RNA修飾的假尿苷市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 RNA修飾的假尿苷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 RNA修飾的假尿苷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • AAT Bioquest, Inc.
  • Agilent Technologies, Inc.
  • Alfa Aesar
  • APExBIO Technology LLC
  • Bio-Synthesis, Inc.
  • Biosynth Ltd.
  • BOC Sciences
  • Carbosynth Ltd.
  • Cayman Chemical Company
  • F. Hoffmann-La Roche Ltd.
  • Jena Bioscience GmbH
  • LGC Limited
  • MedChemExpress LLC
  • Merck KGaA
  • New England Biolabs, Inc.
  • Selleck Chemicals LLC
  • Thermo Fisher Scientific Inc.
  • Toronto Research Chemicals Inc.
  • TriLink BioTechnologies, LLC

第17章 主要專家

Product Code: MRR-537DB9F46E35

The RNA Modified Pseudouridine Market is projected to grow by USD 235.48 million at a CAGR of 12.05% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 106.15 million
Estimated Year [2026] USD 124.15 million
Forecast Year [2032] USD 235.48 million
CAGR (%) 12.05%

RNA-Modified Pseudouridine: Executive Overview

RNA-modified pseudouridine is a chemically modified nucleoside used to alter RNA stability, translation, innate immune recognition, and formulation performance. Its relevance spans messenger RNA therapeutics, vaccines, gene-editing systems, and research reagents. Development priorities center on reproducible synthesis, high-purity analytical control, scalable manufacturing, and evidence linking specific modification profiles to clinical and functional outcomes.

Platform Integration Is Reshaping RNA Development

The landscape is shifting from proof-of-concept RNA design toward integrated development platforms that connect sequence engineering, nucleoside chemistry, delivery systems, process development, and quality control. Greater attention is being paid to impurity profiles, immune activation, storage stability, and lot-to-lot consistency. Regulatory expectations are also encouraging developers to characterize modified RNA materials more comprehensively across discovery, clinical development, and manufacturing.

Artificial Intelligence Accelerates Design and Quality Workflows

Artificial intelligence can support modified-RNA research by prioritizing sequences, modeling structure and translation behavior, identifying potentially immunogenic motifs, and optimizing analytical workflows. Machine-learning tools may also help correlate synthesis conditions with impurity patterns and product performance. Their value depends on well-annotated experimental data, transparent validation, human review, and controls that prevent model outputs from substituting for laboratory, toxicology, or regulatory evidence.

Regional Insights: Capabilities Are Broadening Across the RNA Ecosystem

North America combines advanced biotechnology infrastructure, translational research, and established regulatory experience. Europe benefits from strong academic networks, pharmaceutical manufacturing expertise, and coordinated scientific programs, while Asia-Pacific is expanding capabilities in nucleic-acid research, process development, and biomanufacturing. Latin America is strengthening research and production linkages, with activity shaped by public-health priorities and technology access. The Middle East is emphasizing innovation ecosystems and specialized healthcare investment, while Africa's opportunities are closely tied to technology transfer, local analytical capacity, and regional manufacturing resilience.

Group Insights: Policy Alignment and Supply Resilience Matter

ASEAN economies are positioned to benefit from coordinated manufacturing, research collaboration, and regional supply-chain development. BRICS countries bring substantial scientific, industrial, and public-health capabilities but require interoperability across regulatory and quality systems. The European Union emphasizes harmonized standards and advanced life-science research; the G7 combines deep financing, research, and regulatory resources. GCC members are prioritizing biotechnology diversification and infrastructure, while NATO countries can draw on broad scientific networks and resilience planning relevant to critical biological supply chains.

Country Insights: Diverse Strengths Shape Adoption Pathways

The United States and Canada provide strong translational, regulatory, and manufacturing capabilities. Germany, France, Italy, Spain, and the United Kingdom contribute established biomedical research, clinical infrastructure, and advanced pharmaceutical quality systems. China, Japan, South Korea, India, and Australia combine growing RNA research with distinctive manufacturing, academic, and healthcare strengths. Brazil and Mexico are important Latin American nodes for research, public-health programs, and regional production. Russia retains scientific and industrial capabilities, although collaboration conditions and access to international inputs can influence development pathways.

Priorities for Industry Leaders

Industry leaders should establish end-to-end control of modified-nucleoside quality, including validated identity, purity, residual-impurity, and functional assays. They should connect chemical design with delivery, translation, immunogenicity, and stability data rather than optimizing each component in isolation. Diversifying qualified suppliers, investing in regional analytical and manufacturing capabilities, and engaging regulators early can reduce execution risk. AI initiatives should focus on auditable use cases supported by strong data governance, while partnerships with academic, clinical, and manufacturing organizations can accelerate evidence generation.

Methodology: Evidence-Led Synthesis of the Market Landscape

This executive summary uses the specified RNA-modified pseudouridine scope and organizes findings across technology, application, geography, stakeholder group, and country dimensions. Insights are framed from established characteristics of modified-RNA development, biomanufacturing, regulation, supply-chain management, and artificial-intelligence application. The analysis intentionally excludes market estimates, market shares, forecasts, and company-specific claims. Geographic and group observations are comparative interpretations of institutional capabilities and development conditions, not quantitative rankings.

Conclusion: Build for Performance, Quality, and Resilience

RNA-modified pseudouridine is becoming an enabling component of broader RNA technology platforms rather than a standalone chemistry consideration. Sustainable progress will depend on linking modification selection to biological performance, delivery, manufacturability, and regulatory evidence. Organizations that combine rigorous analytics, scalable production, responsible AI, and geographically resilient partnerships will be better positioned to translate laboratory advances into dependable therapeutic, vaccine, and research applications.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. RNA Modified Pseudouridine Market, by Type

  • 7.1. Introduction
  • 7.2. 1-Methylpseudouridine
  • 7.3. Pseudouridine

8. RNA Modified Pseudouridine Market, by Form

  • 8.1. Introduction
  • 8.2. Liquid
  • 8.3. Powder

9. RNA Modified Pseudouridine Market, by Purity Grade

  • 9.1. Introduction
  • 9.2. Analytical Grade
  • 9.3. HPLC Grade

10. RNA Modified Pseudouridine Market, by Application

  • 10.1. Introduction
  • 10.2. Academic Research
  • 10.3. Diagnostic Research
  • 10.4. mRNA Therapeutics
  • 10.5. mRNA Vaccines

11. RNA Modified Pseudouridine Market, by End User

  • 11.1. Introduction
  • 11.2. Academic And Research Institutes
  • 11.3. Contract Research Organizations
  • 11.4. Pharmaceutical And Biotechnology Companies

12. RNA Modified Pseudouridine Market, by Region

  • 12.1. Introduction
  • 12.2. Asia-Pacific
  • 12.3. North America
  • 12.4. Latin America
  • 12.5. Europe
  • 12.6. Middle East
  • 12.7. Africa

13. RNA Modified Pseudouridine Market, by Group

  • 13.1. Introduction
  • 13.2. ASEAN
  • 13.3. GCC
  • 13.4. European Union
  • 13.5. BRICS
  • 13.6. G7
  • 13.7. NATO

14. RNA Modified Pseudouridine Market, by Country

  • 14.1. Introduction
  • 14.2. United States
  • 14.3. Canada
  • 14.4. Mexico
  • 14.5. Brazil
  • 14.6. United Kingdom
  • 14.7. Germany
  • 14.8. France
  • 14.9. Russia
  • 14.10. Italy
  • 14.11. Spain
  • 14.12. China
  • 14.13. India
  • 14.14. Japan
  • 14.15. Australia
  • 14.16. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. Market Concentration Analysis, 2025
    • 15.2.1. Concentration Ratio (CR)
    • 15.2.2. Herfindahl Hirschman Index (HHI)
  • 15.3. Recent Developments & Impact Analysis, 2025
  • 15.4. Product Portfolio Analysis, 2025
  • 15.5. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. AAT Bioquest, Inc.
  • 16.2. Agilent Technologies, Inc.
  • 16.3. Alfa Aesar
  • 16.4. APExBIO Technology LLC
  • 16.5. Bio-Synthesis, Inc.
  • 16.6. Biosynth Ltd.
  • 16.7. BOC Sciences
  • 16.8. Carbosynth Ltd.
  • 16.9. Cayman Chemical Company
  • 16.10. F. Hoffmann-La Roche Ltd.
  • 16.11. Jena Bioscience GmbH
  • 16.12. LGC Limited
  • 16.13. MedChemExpress LLC
  • 16.14. Merck KGaA
  • 16.15. New England Biolabs, Inc.
  • 16.16. Selleck Chemicals LLC
  • 16.17. Thermo Fisher Scientific Inc.
  • 16.18. Toronto Research Chemicals Inc.
  • 16.19. TriLink BioTechnologies, LLC

17. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global RNA Modified Pseudouridine Market, Years Considered for the Study
  • FIGURE 2. Global RNA Modified Pseudouridine Market, Research Design
  • FIGURE 3. Global RNA Modified Pseudouridine Market, Research Framework
  • FIGURE 4. Global RNA Modified Pseudouridine Market, Data Triangulation
  • FIGURE 5. Global RNA Modified Pseudouridine Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global RNA Modified Pseudouridine Market Size, by Type, 2025 vs 2032 (%)
  • FIGURE 7. Global RNA Modified Pseudouridine Market Size, by Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global RNA Modified Pseudouridine Market Size, by Form, 2025 vs 2032 (%)
  • FIGURE 9. Global RNA Modified Pseudouridine Market Size, by Form, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global RNA Modified Pseudouridine Market Size, by Purity Grade, 2025 vs 2032 (%)
  • FIGURE 11. Global RNA Modified Pseudouridine Market Size, by Purity Grade, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global RNA Modified Pseudouridine Market Size, by Application, 2025 vs 2032 (%)
  • FIGURE 13. Global RNA Modified Pseudouridine Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global RNA Modified Pseudouridine Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 15. Global RNA Modified Pseudouridine Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global RNA Modified Pseudouridine Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 17. Global RNA Modified Pseudouridine Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global RNA Modified Pseudouridine Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 19. Global RNA Modified Pseudouridine Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 20. Global RNA Modified Pseudouridine Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 21. Global RNA Modified Pseudouridine Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global RNA Modified Pseudouridine Market Segmentation & Coverage
  • TABLE 2. Global RNA Modified Pseudouridine Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global RNA Modified Pseudouridine Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 4. Global 1-Methylpseudouridine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global 1-Methylpseudouridine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global 1-Methylpseudouridine Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Pseudouridine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Pseudouridine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Pseudouridine Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global RNA Modified Pseudouridine Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 11. Global Liquid Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 12. Global Liquid Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 13. Global Liquid Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 14. Global Powder Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 15. Global Powder Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 16. Global Powder Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 17. Global RNA Modified Pseudouridine Market Size, by Purity Grade, 2017-2032 (USD Million)
  • TABLE 18. Global Analytical Grade Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 19. Global Analytical Grade Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 20. Global Analytical Grade Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 21. Global HPLC Grade Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 22. Global HPLC Grade Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 23. Global HPLC Grade Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 24. Global RNA Modified Pseudouridine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 25. Global Academic Research Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 26. Global Academic Research Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 27. Global Academic Research Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 28. Global Diagnostic Research Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 29. Global Diagnostic Research Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 30. Global Diagnostic Research Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 31. Global mRNA Therapeutics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 32. Global mRNA Therapeutics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 33. Global mRNA Therapeutics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 34. Global mRNA Vaccines Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 35. Global mRNA Vaccines Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 36. Global mRNA Vaccines Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 37. Global RNA Modified Pseudouridine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 38. Global Academic And Research Institutes Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 39. Global Academic And Research Institutes Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 40. Global Academic And Research Institutes Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 41. Global Contract Research Organizations Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 42. Global Contract Research Organizations Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 43. Global Contract Research Organizations Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 44. Global Pharmaceutical And Biotechnology Companies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 45. Global Pharmaceutical And Biotechnology Companies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 46. Global Pharmaceutical And Biotechnology Companies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 47. Global RNA Modified Pseudouridine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 48. Asia-Pacific RNA Modified Pseudouridine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 49. Asia-Pacific RNA Modified Pseudouridine Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 50. Asia-Pacific RNA Modified Pseudouridine Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 51. Asia-Pacific RNA Modified Pseudouridine Market Size, by Purity Grade, 2017-2032 (USD Million)
  • TABLE 52. Asia-Pacific RNA Modified Pseudouridine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 53. Asia-Pacific RNA Modified Pseudouridine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 54. North America RNA Modified Pseudouridine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 55. North America RNA Modified Pseudouridine Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 56. North America RNA Modified Pseudouridine Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 57. North America RNA Modified Pseudouridine Market Size, by Purity Grade, 2017-2032 (USD Million)
  • TABLE 58. North America RNA Modified Pseudouridine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 59. North America RNA Modified Pseudouridine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 60. Latin America RNA Modified Pseudouridine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 61. Latin America RNA Modified Pseudouridine Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 62. Latin America RNA Modified Pseudouridine Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 63. Latin America RNA Modified Pseudouridine Market Size, by Purity Grade, 2017-2032 (USD Million)
  • TABLE 64. Latin America RNA Modified Pseudouridine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 65. Latin America RNA Modified Pseudouridine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 66. Europe RNA Modified Pseudouridine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 67. Europe RNA Modified Pseudouridine Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 68. Europe RNA Modified Pseudouridine Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 69. Europe RNA Modified Pseudouridine Market Size, by Purity Grade, 2017-2032 (USD Million)
  • TABLE 70. Europe RNA Modified Pseudouridine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 71. Europe RNA Modified Pseudouridine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 72. Middle East RNA Modified Pseudouridine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 73. Middle East RNA Modified Pseudouridine Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 74. Middle East RNA Modified Pseudouridine Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 75. Middle East RNA Modified Pseudouridine Market Size, by Purity Grade, 2017-2032 (USD Million)
  • TABLE 76. Middle East RNA Modified Pseudouridine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 77. Middle East RNA Modified Pseudouridine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 78. Africa RNA Modified Pseudouridine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 79. Africa RNA Modified Pseudouridine Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 80. Africa RNA Modified Pseudouridine Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 81. Africa RNA Modified Pseudouridine Market Size, by Purity Grade, 2017-2032 (USD Million)
  • TABLE 82. Africa RNA Modified Pseudouridine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 83. Africa RNA Modified Pseudouridine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 84. Global RNA Modified Pseudouridine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 85. ASEAN RNA Modified Pseudouridine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 86. ASEAN RNA Modified Pseudouridine Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 87. ASEAN RNA Modified Pseudouridine Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 88. ASEAN RNA Modified Pseudouridine Market Size, by Purity Grade, 2017-2032 (USD Million)
  • TABLE 89. ASEAN RNA Modified Pseudouridine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 90. ASEAN RNA Modified Pseudouridine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 91. GCC RNA Modified Pseudouridine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 92. GCC RNA Modified Pseudouridine Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 93. GCC RNA Modified Pseudouridine Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 94. GCC RNA Modified Pseudouridine Market Size, by Purity Grade, 2017-2032 (USD Million)
  • TABLE 95. GCC RNA Modified Pseudouridine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 96. GCC RNA Modified Pseudouridine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 97. European Union RNA Modified Pseudouridine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 98. European Union RNA Modified Pseudouridine Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 99. European Union RNA Modified Pseudouridine Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 100. European Union RNA Modified Pseudouridine Market Size, by Purity Grade, 2017-2032 (USD Million)
  • TABLE 101. European Union RNA Modified Pseudouridine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 102. European Union RNA Modified Pseudouridine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 103. BRICS RNA Modified Pseudouridine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 104. BRICS RNA Modified Pseudouridine Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 105. BRICS RNA Modified Pseudouridine Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 106. BRICS RNA Modified Pseudouridine Market Size, by Purity Grade, 2017-2032 (USD Million)
  • TABLE 107. BRICS RNA Modified Pseudouridine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 108. BRICS RNA Modified Pseudouridine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 109. G7 RNA Modified Pseudouridine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 110. G7 RNA Modified Pseudouridine Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 111. G7 RNA Modified Pseudouridine Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 112. G7 RNA Modified Pseudouridine Market Size, by Purity Grade, 2017-2032 (USD Million)
  • TABLE 113. G7 RNA Modified Pseudouridine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 114. G7 RNA Modified Pseudouridine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 115. NATO RNA Modified Pseudouridine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 116. NATO RNA Modified Pseudouridine Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 117. NATO RNA Modified Pseudouridine Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 118. NATO RNA Modified Pseudouridine Market Size, by Purity Grade, 2017-2032 (USD Million)
  • TABLE 119. NATO RNA Modified Pseudouridine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 120. NATO RNA Modified Pseudouridine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 121. Global RNA Modified Pseudouridine Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 122. United States RNA Modified Pseudouridine Market Size, 2017-2032 (USD Million)
  • TABLE 123. United States RNA Modified Pseudouridine Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 124. United States RNA Modified Pseudouridine Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 125. United States RNA Modified Pseudouridine Market Size, by Purity Grade, 2017-2032 (USD Million)
  • TABLE 126. United States RNA Modified Pseudouridine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 127. United States RNA Modified Pseudouridine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 128. Canada RNA Modified Pseudouridine Market Size, 2017-2032 (USD Million)
  • TABLE 129. Canada RNA Modified Pseudouridine Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 130. Canada RNA Modified Pseudouridine Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 131. Canada RNA Modified Pseudouridine Market Size, by Purity Grade, 2017-2032 (USD Million)
  • TABLE 132. Canada RNA Modified Pseudouridine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 133. Canada RNA Modified Pseudouridine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 134. Mexico RNA Modified Pseudouridine Market Size, 2017-2032 (USD Million)
  • TABLE 135. Mexico RNA Modified Pseudouridine Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 136. Mexico RNA Modified Pseudouridine Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 137. Mexico RNA Modified Pseudouridine Market Size, by Purity Grade, 2017-2032 (USD Million)
  • TABLE 138. Mexico RNA Modified Pseudouridine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 139. Mexico RNA Modified Pseudouridine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 140. Brazil RNA Modified Pseudouridine Market Size, 2017-2032 (USD Million)
  • TABLE 141. Brazil RNA Modified Pseudouridine Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 142. Brazil RNA Modified Pseudouridine Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 143. Brazil RNA Modified Pseudouridine Market Size, by Purity Grade, 2017-2032 (USD Million)
  • TABLE 144. Brazil RNA Modified Pseudouridine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 145. Brazil RNA Modified Pseudouridine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 146. United Kingdom RNA Modified Pseudouridine Market Size, 2017-2032 (USD Million)
  • TABLE 147. United Kingdom RNA Modified Pseudouridine Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 148. United Kingdom RNA Modified Pseudouridine Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 149. United Kingdom RNA Modified Pseudouridine Market Size, by Purity Grade, 2017-2032 (USD Million)
  • TABLE 150. United Kingdom RNA Modified Pseudouridine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 151. United Kingdom RNA Modified Pseudouridine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 152. Germany RNA Modified Pseudouridine Market Size, 2017-2032 (USD Million)
  • TABLE 153. Germany RNA Modified Pseudouridine Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 154. Germany RNA Modified Pseudouridine Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 155. Germany RNA Modified Pseudouridine Market Size, by Purity Grade, 2017-2032 (USD Million)
  • TABLE 156. Germany RNA Modified Pseudouridine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 157. Germany RNA Modified Pseudouridine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 158. France RNA Modified Pseudouridine Market Size, 2017-2032 (USD Million)
  • TABLE 159. France RNA Modified Pseudouridine Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 160. France RNA Modified Pseudouridine Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 161. France RNA Modified Pseudouridine Market Size, by Purity Grade, 2017-2032 (USD Million)
  • TABLE 162. France RNA Modified Pseudouridine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 163. France RNA Modified Pseudouridine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 164. Russia RNA Modified Pseudouridine Market Size, 2017-2032 (USD Million)
  • TABLE 165. Russia RNA Modified Pseudouridine Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 166. Russia RNA Modified Pseudouridine Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 167. Russia RNA Modified Pseudouridine Market Size, by Purity Grade, 2017-2032 (USD Million)
  • TABLE 168. Russia RNA Modified Pseudouridine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 169. Russia RNA Modified Pseudouridine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 170. Italy RNA Modified Pseudouridine Market Size, 2017-2032 (USD Million)
  • TABLE 171. Italy RNA Modified Pseudouridine Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 172. Italy RNA Modified Pseudouridine Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 173. Italy RNA Modified Pseudouridine Market Size, by Purity Grade, 2017-2032 (USD Million)
  • TABLE 174. Italy RNA Modified Pseudouridine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 175. Italy RNA Modified Pseudouridine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 176. Spain RNA Modified Pseudouridine Market Size, 2017-2032 (USD Million)
  • TABLE 177. Spain RNA Modified Pseudouridine Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 178. Spain RNA Modified Pseudouridine Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 179. Spain RNA Modified Pseudouridine Market Size, by Purity Grade, 2017-2032 (USD Million)
  • TABLE 180. Spain RNA Modified Pseudouridine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 181. Spain RNA Modified Pseudouridine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 182. China RNA Modified Pseudouridine Market Size, 2017-2032 (USD Million)
  • TABLE 183. China RNA Modified Pseudouridine Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 184. China RNA Modified Pseudouridine Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 185. China RNA Modified Pseudouridine Market Size, by Purity Grade, 2017-2032 (USD Million)
  • TABLE 186. China RNA Modified Pseudouridine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 187. China RNA Modified Pseudouridine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 188. India RNA Modified Pseudouridine Market Size, 2017-2032 (USD Million)
  • TABLE 189. India RNA Modified Pseudouridine Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 190. India RNA Modified Pseudouridine Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 191. India RNA Modified Pseudouridine Market Size, by Purity Grade, 2017-2032 (USD Million)
  • TABLE 192. India RNA Modified Pseudouridine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 193. India RNA Modified Pseudouridine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 194. Japan RNA Modified Pseudouridine Market Size, 2017-2032 (USD Million)
  • TABLE 195. Japan RNA Modified Pseudouridine Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 196. Japan RNA Modified Pseudouridine Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 197. Japan RNA Modified Pseudouridine Market Size, by Purity Grade, 2017-2032 (USD Million)
  • TABLE 198. Japan RNA Modified Pseudouridine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 199. Japan RNA Modified Pseudouridine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 200. Australia RNA Modified Pseudouridine Market Size, 2017-2032 (USD Million)
  • TABLE 201. Australia RNA Modified Pseudouridine Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 202. Australia RNA Modified Pseudouridine Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 203. Australia RNA Modified Pseudouridine Market Size, by Purity Grade, 2017-2032 (USD Million)
  • TABLE 204. Australia RNA Modified Pseudouridine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 205. Australia RNA Modified Pseudouridine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 206. South Korea RNA Modified Pseudouridine Market Size, 2017-2032 (USD Million)
  • TABLE 207. South Korea RNA Modified Pseudouridine Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 208. South Korea RNA Modified Pseudouridine Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 209. South Korea RNA Modified Pseudouridine Market Size, by Purity Grade, 2017-2032 (USD Million)
  • TABLE 210. South Korea RNA Modified Pseudouridine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 211. South Korea RNA Modified Pseudouridine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 212. Global RNA Modified Pseudouridine Market Share, by Key Player, 2025
  • TABLE 213. Global RNA Modified Pseudouridine Market, Key Experts